Please note that the details of this Challenge are no longer open. This challenge is awarded and is no longer accepting new submissions. You can:
Challenge Mobilization, Stimulation, and Differentiation of Endogenous Stem Cells
Mobilization, Stimulation, and Differentiation of Endogenous Stem Cells
STATUS: Awarded
Active Solvers: 133
Posted: Apr 25 2016
Challenge ID: 9933855
 
Team Project Rooms are available on this Challenge. Team Share Challenge Share
Abstract

1. The Challenge and qualification for the award

During early development, embryonic stem cells are undifferentiated cells that can be stimulated to proliferate and develop into all different cell types. In adults, these endogenous cells are found in tissues and they can divide either to replenish the stem cell population or differentiate into specialized cells of the tissue in which they reside. These adult stem cells function as an internal maintenance or repair system, so it would be beneficial to be able to direct and enhance this regenerative capacity. Therefore, Boehringer Ingelheim (the Seeker) desires the identification of new molecular mechanisms and pathways involved in mobilization, stimulation, and differentiation of endogenous stem cells. 

All submitted solutions will be considered for the award. There will be a guaranteed award for at least one submitted solution. The total payout will be $15,000, with the possibility to distribute it amongst one or more Solvers, with at least one award being no smaller than $5,000 and no award being smaller than $1,000. 

2. Additional application for Research Funding

In addition to consideration for the award for the submitted solutions, Solvers with appropriate qualifications and expertise having access to a suitable research laboratory and equipment can apply for research funding (“Research Funding”) to execute the research plan that is proposed in the solution. The selection of candidates for Research Funding will be conducted after completion of this Challenge and will require the submission of additional information. The decision to fund research will be at the discretion of the Seeker. 

This is an Ideation Challenge with a guaranteed award for at least one submitted solution.

Submissions to this Challenge including additional optional application for Research Funding must be received by 11:59 PM (US Eastern Time) on June 24, 2016. Late submissions will not be considered.

Overview

THE CHALLENGE

Regenerative medicine is a growing field that focuses on the repair or replacement of damaged or diseased tissues. Stem cells that remain undifferentiated have the ability to self-renew. Of the two main types of stem cells, embryonic stem cells can develop into any cell type in the body, whereas adult stem cells are more limited, in that they are only capable of maturing into cell types from their tissue of origin. The unlimited potential of embryonic stem cells is attractive, yet the reprogramming of adult stem cells to pluripotent stem cells may be the key to cell replacement therapy. The clinical effectiveness of stem cell therapy is ultimately linked to our understanding of endogenous stem cells and their biology within the human body. Therefore, Boehringer Ingelheim (the Seeker) desires the identification of new molecular mechanisms and pathways involved in mobilization, stimulation, and differentiation of endogenous stem cells. 

This is an Ideation Challenge, which has the following unique features:

  • There is a guaranteed award.  The award(s) will be paid to the best submission(s) as solely determined by the Seeker. The total payout will be $15,000, with the possibility to distribute it amongst one or more Solvers, with at least one award being no smaller than $5,000 and no award being smaller than $1,000. 
  • The Solvers are not required to transfer exclusive intellectual property rights to the Seeker.  Rather, by submitting a proposal, the Solver grants to the Seeker a royalty-free, perpetual, and non-exclusive license to use any information included in this proposal according to the terms and conditions as laid down in the InnoCentive Ideation Challenge-Specific Agreement.

  • APPLICATION FOR RESEARCH FUNDING

    Solvers with appropriate qualification and expertise having access to a suitable research laboratory and equipment can, in addition, apply for Research Funding to execute the research plan that is proposed in the solution. The selection of candidates for Research Funding will be conducted after completion of the Challenge and will require the submission of additional information. The decision to fund research will be at the sole discretion of the Seeker. 

    InnoCentive will inform Solvers considered for Research Funding within 60 days after completion of the Challenge and will provide Seeker contact information for the development of the research collaboration as applicable. The definitive research plan, amount of funding, and the contractual details of the research collaboration will be negotiated with the Solver and his/her responsible institutional representatives following mutual acceptance of the research plan. 

    Solvers may be awarded for the (i) submitted solution and may be (ii) selected for Research Funding independently of being awarded. In particular, selection of a solution for the award does not automatically lead to a selection for Research Funding and vice versa.

After the Challenge deadline, the Seeker will complete the review process and make a decision with regards to the Winning Solution(s). All Solvers that submit a proposal will be notified on the status of their submissions; however, no detailed evaluation of individual submissions will be provided

ABOUT THE SEEKER

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 145 affiliates and a total of around 47,500 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine. 

In 2015, Boehringer Ingelheim achieved net sales of about 14.8 billion euros. R&D expenditure corresponds to 20.3 per cent of its net sales. 

For more information please visit www.boehringer-ingelheim.com.

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an InnoCentive Ideation™ Challenge?

An InnoCentive Ideation™ Challenge is a broad question formulated to obtain access to new ideas, similar to a global brainstorm for producing a breakthrough idea or market survey which may include ideas for a new product line, a new commercial application for a current product, or even a viral marketing idea to recruit new customers. Ideation™ Challenge submissions are typically about two written pages, and Seekers receive a non-exclusive, perpetual license to use all submissions.

In an Ideation™ Challenge, Solvers may:

  • Submit ideas of their own
  • Submit third party information that they have the right to use and further the authority to convey that right and the right to use and develop derivative works to Seekers
  • Submit information considered in the public domain without any limitations on use

Solvers should not reveal any confidential information in their submissions. Often the Ideation™ Challenge will be followed by one or more of the other three Challenge types to further develop the ideas and gain Intellectual Property protection when the concept has been well-defined.

Share This Challenge
InnoCentive Trust Partners